Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2014; 5(5): 697-710
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.697
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.697
Targeting inflammation in diabetes: Newer therapeutic options
Neeraj Kumar Agrawal, Saket Kant, Department of Endocrinology and Metabolism, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India
Author contributions: Agrawal NK and Kant S made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; and final approval of the version to be published.
Correspondence to: Dr. Neeraj Kumar Agrawal, Associate Professor, Department of Endocrinology and Metabolism, Institiute of Medical Sciences, Banaras Hindu University, Pandit Madan Mohan Malviya Rd, Varanasi 221005, India. drnkavns@gmail.com
Telephone: +91-941-5224741 Fax: +91-542-2367568
Received: December 27, 2013
Revised: April 24, 2014
Accepted: May 29, 2014
Published online: October 15, 2014
Processing time: 232 Days and 18.3 Hours
Revised: April 24, 2014
Accepted: May 29, 2014
Published online: October 15, 2014
Processing time: 232 Days and 18.3 Hours
Core Tip
Core tip: The burden of diabetes and its complications is increasing worldwide. To control this pandemic, drugs targeting different areas of the pathogenesis of diabetes and its complications are needed. Inflammation plays a key role in the natural history of diabetes during the progression from pre-diabetes to diabetes, including decreased beta cell secretory capacity and insulin resistance. Insulin resistance is an important part of the metabolic syndrome and plays a role in the pathogenesis of various macrovascular complications. Drugs targeting inflammatory pathways represent a fresh approach in the treatment of diabetes and its complications.